Maria Rosario Pac-Sa
Research Subjects
Maria Rosario Pac-Sa has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Arnedo-Pena
Centro de Salud Pública, Castelló de la Plana, Spain; CIBER de Epidemiologia y Salud Pública (CI-BERESP), Madrid; and Departamento de Ciencias de la Salud, Universidad Pública de Navarra, Spain;, Spain
17 shared publications - Manuel Sánchez-Urbano
Emergency Service Department, University Hospital de la Plana, 12540 Vila-Real, Spain
16 shared publications - Raquel Ruiz-Puig
Emergency Service Department, University Hospital de la Plana, 12540 Vila-Real, Spain
14 shared publications - Cristina Notari-Rodríguez
Emergency Service Department, University Hospital de la Plana, 12540 Vila-Real, Spain
13 shared publications - Diego Sala-Trull
Emergency Service Department, University Hospital de la Plana, 12540 Vila-Real, Spain
13 shared publications - Gema Badenes-Marques
Emergency Service Department, University Hospital de la Plana, 12540 Vila-Real, Spain
12 shared publications
Latest Publications
- Open Access
- 3 July 2026
- Published by MDPI AG in Preprints.org
Determinants of Long COVID Persistence and Recovery in the Borriana COVID-19 Cohort During the Period 2020–2023: A Prospective Population-Based Cohort Study
Background: After more than four years of the COVID-19 pandemic, the long COVID syndrome (LC) still affects a considerable population, and factors associated with the evolution of LC have been scarcely studied. Our objective was to estimate determinants related to long COVID persistence and recovery. Methods: We carried out a prospective population-based cohort study within the Borriana COVID-19 cohort (Spain), from May 2020 to August 2023. All participants had a confirmed laboratory SARS-CoV-2 infection, and we used the World Health Organization definition for LC, whereas recovery status was self-reported by the participants. Multivariable robust Poisson regression models were used in the statistical analysis. Results: In the cohort of 722 participants (response rate 63.8%), of whom 644 with SARS-CoV-2 infection, 184 suffered from LC (28.6%), and 135 patients remained affected (73.4%) with a mean age 42.0 ±14.5, being 94 women, of whom 49 have recovered, a mean age 41.3 ± 16.3, 35 women. Medical consultation for LC sequelae was 45.7%. Determinant related to LC persistence were old age, previous chronic disease, the AB blood group, and hospitalization. SARS-CoV-2 vaccination increased LC recovery. Conclusions: The persistent LC rate was high, and determinants of LC were estimated. Maintaining the follow-up of the cohort, increasing medical assistance for LC persistence, and improving health levels are recommended.
- 3 July 2026
- Published by MDPI AG in Preprints.org
Open AccessDeterminants of Long COVID Persistence and Recovery in the Borriana COVID-19 Cohort During the Period 2020–2023: A Prospective Population-Based Cohort Study
Background: After more than four years of the COVID-19 pandemic, the long COVID syndrome (LC) still affects a considerable population, and factors associated with the evolution of LC have been scarcely studied. Our objective was to estimate determinants related to long COVID persistence and recovery. Methods: We carried out a prospective population-based cohort study within the Borriana COVID-19 cohort (Spain), from May 2020 to August 2023. All participants had a confirmed laboratory SARS-CoV-2 infection, and we used the World Health Organization definition for LC, whereas recovery status was self-reported by the participants. Multivariable robust Poisson regression models were used in the statistical analysis. Results: In the cohort of 722 participants (response rate 63.8%), of whom 644 with SARS-CoV-2 infection, 184 suffered from LC (28.6%), and 135 patients remained affected (73.4%) with a mean age 42.0 ±14.5, being 94 women, of whom 49 have recovered, a mean age 41.3 ± 16.3, 35 women. Medical consultation for LC sequelae was 45.7%. Determinant related to LC persistence were old age, previous chronic disease, the AB blood group, and hospitalization. SARS-CoV-2 vaccination increased LC recovery. Conclusions: The persistent LC rate was high, and determinants of LC were estimated. Maintaining the follow-up of the cohort, increasing medical assistance for LC persistence, and improving health levels are recommended.
- Open Access
Risk and Protective Factors for Long COVID Incidence in the Borriana COVID-19 Cohort from 2020 to 2023: A Prospective Population-Based Cohort Study
Background and Objective: After SARS-CoV-2 infection, Long COVID (LC) syndrome has occurred in a high proportion of patients, affecting their health. The aim of this study was to estimate the incidence of LC, as well as its risk and protective factors. Materials and Methods: We conducted a prospective population-based cohort study of the Borriana COVID-19 cohort (Castellon Province, Valencia Community, Spain) from May 2020 to August 2023, with a follow-up of 40 months, using the LC definition given by the World Health Organization. Inverse probability-weighted regression adjustment was applied in the statistical analysis. Results: With a participation rate of 63.8% and a total of 722 participants, the mean age was 37.7 ± 17.4 years, and 460 (62.3%) were female. Among them, 644 had experienced a SARS-CoV-2 infection, and 184 developed LC, corresponding to a cumulative incidence of 28.6%. At the time of follow-up, 135 patients remained affected by LC, and one LC-related death was recorded. Significant risk factors for LC included older age, female sex, being part of a small family, having a chronic disease, SARS-CoV-2 exposure, and disease severity. Asymptomatic COVID-19 infection and SARS-CoV-2 vaccination were significantly protective factors. Conclusions: A substantial incidence of LC was observed, along with a low recovery rate. Several risk and protective factors were identified. Continued follow-up of this cohort, improved medical care for patients with non-recovered LC, ongoing surveillance of SARS-CoV-2 infections, and vaccination of the at-risk populations against SARS-CoV-2 are recommended.
Open AccessRisk and Protective Factors for Long COVID Incidence in the Borriana COVID-19 Cohort from 2020 to 2023: A Prospective Population-Based Cohort Study
Background and Objective: After SARS-CoV-2 infection, Long COVID (LC) syndrome has occurred in a high proportion of patients, affecting their health. The aim of this study was to estimate the incidence of LC, as well as its risk and protective factors. Materials and Methods: We conducted a prospective population-based cohort study of the Borriana COVID-19 cohort (Castellon Province, Valencia Community, Spain) from May 2020 to August 2023, with a follow-up of 40 months, using the LC definition given by the World Health Organization. Inverse probability-weighted regression adjustment was applied in the statistical analysis. Results: With a participation rate of 63.8% and a total of 722 participants, the mean age was 37.7 ± 17.4 years, and 460 (62.3%) were female. Among them, 644 had experienced a SARS-CoV-2 infection, and 184 developed LC, corresponding to a cumulative incidence of 28.6%. At the time of follow-up, 135 patients remained affected by LC, and one LC-related death was recorded. Significant risk factors for LC included older age, female sex, being part of a small family, having a chronic disease, SARS-CoV-2 exposure, and disease severity. Asymptomatic COVID-19 infection and SARS-CoV-2 vaccination were significantly protective factors. Conclusions: A substantial incidence of LC was observed, along with a low recovery rate. Several risk and protective factors were identified. Continued follow-up of this cohort, improved medical care for patients with non-recovered LC, ongoing surveillance of SARS-CoV-2 infections, and vaccination of the at-risk populations against SARS-CoV-2 are recommended.
- Open Access
- 13 March 2026
- Published by MDPI AG in Preprints.org
Risk and Protective Factors of Long COVID Incidence in the Borriana COVID-19 Cohort from 2020 to 2023: A Prospective Population-Based Cohort Study
Background and Objective: After a SARS-CoV-2 infection, a Long COVID (LC) syndrome occurred in a high proportion of patients with affecting their health. Estimating the incidence, risk and protective factors of LC was the aim of our study. Material and Methods: We performed a prospective population-based cohort study on the Borriana COVID-19 cohort (Castellon province, Valencia Community, Spain) from May 2020 to August 2023 with a follow-up of 40 months, and considering the LC definition from the World Health Organization. We used inverse probability weighted regression. Results: With a response rate of 63.8% of a total of 722 participants, the average age was 37.7±17.4 years with 460 (62.3%) females, 644 had suffered a SARS-CoV-2 infection, and 184 suffered LC with a cumulative incidence of 28.6%. A total of 135 patients with LC remained affected, and a death associated with the syndrome occurred in 0.54% of them. Significant risk factors for LC were older age, female, chronic disease, SARS-CoV-2 exposure, reinfections and severity. Asymptomatic cases and SARS-CoV-2 vaccinations were significantly protective factors. Conclusions: A high incidence of LC was found with low recovery rate, and several risk and protective factors. Continued follow-up for non-recovered LC patients, surveillance of infections, and a SARS-CoV-2 vaccination for an at-risk population can be recommended.
- 13 March 2026
- Published by MDPI AG in Preprints.org
Open AccessRisk and Protective Factors of Long COVID Incidence in the Borriana COVID-19 Cohort from 2020 to 2023: A Prospective Population-Based Cohort Study
Background and Objective: After a SARS-CoV-2 infection, a Long COVID (LC) syndrome occurred in a high proportion of patients with affecting their health. Estimating the incidence, risk and protective factors of LC was the aim of our study. Material and Methods: We performed a prospective population-based cohort study on the Borriana COVID-19 cohort (Castellon province, Valencia Community, Spain) from May 2020 to August 2023 with a follow-up of 40 months, and considering the LC definition from the World Health Organization. We used inverse probability weighted regression. Results: With a response rate of 63.8% of a total of 722 participants, the average age was 37.7±17.4 years with 460 (62.3%) females, 644 had suffered a SARS-CoV-2 infection, and 184 suffered LC with a cumulative incidence of 28.6%. A total of 135 patients with LC remained affected, and a death associated with the syndrome occurred in 0.54% of them. Significant risk factors for LC were older age, female, chronic disease, SARS-CoV-2 exposure, reinfections and severity. Asymptomatic cases and SARS-CoV-2 vaccinations were significantly protective factors. Conclusions: A high incidence of LC was found with low recovery rate, and several risk and protective factors. Continued follow-up for non-recovered LC patients, surveillance of infections, and a SARS-CoV-2 vaccination for an at-risk population can be recommended.
- Open Access
- 19 December 2025
- Published by MDPI AG in Epidemiologia
- Vol. 7 (1) , 1
SARS-CoV-2 mRNA Vaccine Effectiveness in the Borriana COVID-19 Cohort: A Prospective Population-Based Cohort Study
Background and Objective: Evaluating vaccine effectiveness (VE) is essential to implementing prevention strategies, and our objective was to estimate the VE of SARS-CoV-2 messenger RNA (mRNA) vaccines in preventing SARS-CoV-2 infection. Materials and Methods: We carried out a population-based, prospective cohort study on the Borriana COVID-19 cohort (Valencia Community, Spain) during the 2021–2023 period, considering all SARS-CoV-2 cases that occurred after the SARS-CoV-2 vaccine campaign started in January 2021 (first approach), as well as only symptomatic cases (second approach). Multivariable robust Poisson regression models were employed. Results: In this cohort with 301 participants, 285 were vaccinated, among whom 228 received only SARS-CoV-2 mRNA vaccines, and 57 received mRNA vaccines and other vaccines. In the first approach, there were 226 cases and 75 non-cases. The adjusted VE for three doses of vaccine was 37% (95% confidence interval [CI]: 22–49%) to prevent infection. In the second approach, with 153 symptomatic cases after excluding 73 asymptomatic cases, the adjusted VE for three doses of vaccine was 50% (95% CI 33–63%) to prevent symptomatic infection. Three doses of vaccine exhibited modest but significant protection against infection and symptomatic infection. Conclusions: This study recommends surveilling SARS-CoV-2 infections and variants, vaccinating at-risk populations, and developing new vaccines.
- 19 December 2025
- Published by MDPI AG in Epidemiologia
- Vol. 7 (1) , 1
Open AccessSARS-CoV-2 mRNA Vaccine Effectiveness in the Borriana COVID-19 Cohort: A Prospective Population-Based Cohort Study
Background and Objective: Evaluating vaccine effectiveness (VE) is essential to implementing prevention strategies, and our objective was to estimate the VE of SARS-CoV-2 messenger RNA (mRNA) vaccines in preventing SARS-CoV-2 infection. Materials and Methods: We carried out a population-based, prospective cohort study on the Borriana COVID-19 cohort (Valencia Community, Spain) during the 2021–2023 period, considering all SARS-CoV-2 cases that occurred after the SARS-CoV-2 vaccine campaign started in January 2021 (first approach), as well as only symptomatic cases (second approach). Multivariable robust Poisson regression models were employed. Results: In this cohort with 301 participants, 285 were vaccinated, among whom 228 received only SARS-CoV-2 mRNA vaccines, and 57 received mRNA vaccines and other vaccines. In the first approach, there were 226 cases and 75 non-cases. The adjusted VE for three doses of vaccine was 37% (95% confidence interval [CI]: 22–49%) to prevent infection. In the second approach, with 153 symptomatic cases after excluding 73 asymptomatic cases, the adjusted VE for three doses of vaccine was 50% (95% CI 33–63%) to prevent symptomatic infection. Three doses of vaccine exhibited modest but significant protection against infection and symptomatic infection. Conclusions: This study recommends surveilling SARS-CoV-2 infections and variants, vaccinating at-risk populations, and developing new vaccines.
- Open Access
- 4 November 2025
- Published by MDPI AG in Preprints.org
SARS-CoV-2 mRNA Vaccine Effectiveness in the Borriana COVID-19 Cohort: A Prospective Population-Based Cohort Study
Evaluation of vaccine effectiveness (VE) was essential to implement strategies of prevention, and our objective was estimated the VE of SARS-CoV-2 messenger RNA (mRNA) vaccines to prevent SARS-CoV-2 infection. We performed a population-based prospective cohort study in the Borriana COVID-19 cohort (Valencia Community, Spain) during the period 2021-2023, with two approaches, considering firstly, all cases occurred after SARS-CoV-2 vaccine campaign started in January 2021, and then secondly, only symptomatic cases. Multivariable robust Poisson regression models were employed. Results: In first approach, of 301 participants, 285 were vaccinated, 228 with only SARS-CoV-2 mRNA vaccines, and 57 with mRNA vaccine and other vaccines. A total of 226 cases occurred with 75 non-cases. Adjusted VE for 3 doses of vaccine received was 37% (95% Confidence interval [CI] 22%-49%). The second approach, with 153 symptomatic cases, excluding 73 asymptomatic cases, adjusted VE for 3 doses of vaccine received was 50% (95% CI 33%-63%). While one or two doses of vaccines presented a low VE with insufficient to protect against infection, 3 doses of vaccine reached modest and significant protection. Exclusion of asymptomatic cases improved the VE estimation. Conclusion: Development of new vaccines is needed to improve control and prevention strategies against SARS-CoV-2.
- 4 November 2025
- Published by MDPI AG in Preprints.org
Open AccessSARS-CoV-2 mRNA Vaccine Effectiveness in the Borriana COVID-19 Cohort: A Prospective Population-Based Cohort Study
Evaluation of vaccine effectiveness (VE) was essential to implement strategies of prevention, and our objective was estimated the VE of SARS-CoV-2 messenger RNA (mRNA) vaccines to prevent SARS-CoV-2 infection. We performed a population-based prospective cohort study in the Borriana COVID-19 cohort (Valencia Community, Spain) during the period 2021-2023, with two approaches, considering firstly, all cases occurred after SARS-CoV-2 vaccine campaign started in January 2021, and then secondly, only symptomatic cases. Multivariable robust Poisson regression models were employed. Results: In first approach, of 301 participants, 285 were vaccinated, 228 with only SARS-CoV-2 mRNA vaccines, and 57 with mRNA vaccine and other vaccines. A total of 226 cases occurred with 75 non-cases. Adjusted VE for 3 doses of vaccine received was 37% (95% Confidence interval [CI] 22%-49%). The second approach, with 153 symptomatic cases, excluding 73 asymptomatic cases, adjusted VE for 3 doses of vaccine received was 50% (95% CI 33%-63%). While one or two doses of vaccines presented a low VE with insufficient to protect against infection, 3 doses of vaccine reached modest and significant protection. Exclusion of asymptomatic cases improved the VE estimation. Conclusion: Development of new vaccines is needed to improve control and prevention strategies against SARS-CoV-2.
- Open Access
- 6 April 2025
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 10 (4) , 98
Vitamin D Status and Incidence of SARS-CoV-2 Reinfections in the Borriana COVID-19 Cohort: A Population-Based Prospective Cohort Study
A deficient vitamin D (VitD) status has been associated with SARS-CoV-2 infections, severity, and mortality. However, this status related to SARS-CoV-2 reinfections has been studied little. Our aim was to quantify the risk of reinfections considering VitD status before reinfection. Methods: We performed a population-based prospective cohort study in Borriana (Valencia Community, Spain) during 2020–2023, measuring 25-hydroxyvitamin D [25(OH)D] levels by electrochemiluminescence. Cox proportional hazards models were employed. Results: Of a total of 644 SARS-CoV-2 cases with confirmed laboratory tests, 378 (58.9%) were included in our study, with an average age of 38.8 years; 241 were females (63.8%), and 127 reinfections occurred (33.6%). SARS-CoV-2 reinfection incidence rates per 1000 person-days by VitD status were 0.50 for a deficient status (p = 0.02). These results can help improve nutritional actions against SARS-CoV-2 reinfections. Conclusions: These results suggest that a VitD status lower than 30 ng/mL showed a higher risk of SARS-CoV-2 reinfection. Achieving and maintaining a sufficient VitD status is recommended to prevent reinfections.
- 6 April 2025
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 10 (4) , 98
Open AccessVitamin D Status and Incidence of SARS-CoV-2 Reinfections in the Borriana COVID-19 Cohort: A Population-Based Prospective Cohort Study
A deficient vitamin D (VitD) status has been associated with SARS-CoV-2 infections, severity, and mortality. However, this status related to SARS-CoV-2 reinfections has been studied little. Our aim was to quantify the risk of reinfections considering VitD status before reinfection. Methods: We performed a population-based prospective cohort study in Borriana (Valencia Community, Spain) during 2020–2023, measuring 25-hydroxyvitamin D [25(OH)D] levels by electrochemiluminescence. Cox proportional hazards models were employed. Results: Of a total of 644 SARS-CoV-2 cases with confirmed laboratory tests, 378 (58.9%) were included in our study, with an average age of 38.8 years; 241 were females (63.8%), and 127 reinfections occurred (33.6%). SARS-CoV-2 reinfection incidence rates per 1000 person-days by VitD status were 0.50 for a deficient status (p = 0.02). These results can help improve nutritional actions against SARS-CoV-2 reinfections. Conclusions: These results suggest that a VitD status lower than 30 ng/mL showed a higher risk of SARS-CoV-2 reinfection. Achieving and maintaining a sufficient VitD status is recommended to prevent reinfections.
- Open Access
- 5 March 2025
- Published by MDPI AG in Preprints.org
Vitamin D Status and Incidence of SARS-CoV-2 Reinfections in the Borriana COVID-19 Cohort: A Population-Based Prospective Cohort Study
A deficient vitamin D (VitD) status has been associated with SARS-CoV-2 infections, severity, and mortality. However, this status related to SARS-CoV-2 reinfections has been little studied. Our aim was to quantify the risk of reinfections considering VitD status before reinfection. Methods: We performed a population-based prospective cohort study in Borriana (Valencia Community, Spain) during 2020-2023 years, measuring 25-hydroxyvitamin D [25(OH)D] levels by electrochemiluminescence. Cox proportional hazards models were employed. Results: Of a total of 644 SARS-CoV-2 cases with confirmed laboratory tests, 378 (58.9%) were included in out study with an average age of 38.8 years, 241 were females (63.8%), and 127 reinfections occurred (33.6%). SARS-CoV-2 reinfection incidence rates per 1000 person-days by VitD status were for a deficient status 0.4983 (< 20 ng/ml), 0.4977 for insufficient (20-29 ng/ml), and 0.3713 for sufficient (≥30ng/ml). Compared with sufficient VitD status, adjusted hazard ratios were 1.79 (95% Confidence Interval [CI] 0.89-3.59) for deficient status and 1.59 (95% CI 1.06-2.38) for insufficient status with a significant inverse dose-response (p=0.02). These results can help improve nutritional actions against SARS-CoV-2 reinfections. Conclusions: These results suggest that a VitD status lower than 30 ng/ml showed a higher risk of SARS-CoV-2 reinfection. Achieving and maintaining a sufficient VitD status is recommended to prevent reinfections.
- 5 March 2025
- Published by MDPI AG in Preprints.org
Open AccessVitamin D Status and Incidence of SARS-CoV-2 Reinfections in the Borriana COVID-19 Cohort: A Population-Based Prospective Cohort Study
A deficient vitamin D (VitD) status has been associated with SARS-CoV-2 infections, severity, and mortality. However, this status related to SARS-CoV-2 reinfections has been little studied. Our aim was to quantify the risk of reinfections considering VitD status before reinfection. Methods: We performed a population-based prospective cohort study in Borriana (Valencia Community, Spain) during 2020-2023 years, measuring 25-hydroxyvitamin D [25(OH)D] levels by electrochemiluminescence. Cox proportional hazards models were employed. Results: Of a total of 644 SARS-CoV-2 cases with confirmed laboratory tests, 378 (58.9%) were included in out study with an average age of 38.8 years, 241 were females (63.8%), and 127 reinfections occurred (33.6%). SARS-CoV-2 reinfection incidence rates per 1000 person-days by VitD status were for a deficient status 0.4983 (< 20 ng/ml), 0.4977 for insufficient (20-29 ng/ml), and 0.3713 for sufficient (≥30ng/ml). Compared with sufficient VitD status, adjusted hazard ratios were 1.79 (95% Confidence Interval [CI] 0.89-3.59) for deficient status and 1.59 (95% CI 1.06-2.38) for insufficient status with a significant inverse dose-response (p=0.02). These results can help improve nutritional actions against SARS-CoV-2 reinfections. Conclusions: These results suggest that a VitD status lower than 30 ng/ml showed a higher risk of SARS-CoV-2 reinfection. Achieving and maintaining a sufficient VitD status is recommended to prevent reinfections.
- Open Access
- 9 August 2024
- Published by MDPI AG in Epidemiologia
- Vol. 5 (3) , 499-510
Underreporting of Cases in the COVID-19 Outbreak of Borriana (Spain) during Mass Gathering Events in March 2020: A Cross-Sectional Study
Determining the number of cases of an epidemic is the first function of epidemiological surveillance. An important underreporting of cases was observed in many locations during the first wave of the COVID-19 pandemic. To estimate this underreporting in the COVID-19 outbreak of Borriana (Valencia Community, Spain) in March 2020, a cross-sectional study was performed in June 2020 querying the public health register. Logistic regression models were used. Of a total of 468 symptomatic COVID-19 cases diagnosed in the outbreak through anti-SARS-CoV-2 serology, 36 cases were reported (7.7%), resulting in an underreporting proportion of 92.3% (95% confidence interval [CI], 89.5–94.6%), with 13 unreported cases for every reported case. Only positive SARS-CoV-2 polymerase chain reaction cases were predominantly reported due to a limited testing capacity and following a national protocol. Significant factors associated with underreporting included no medical assistance for COVID-19 disease, with an adjusted odds ratio [aOR] of 10.83 (95% CI 2.49–47.11); no chronic illness, aOR = 2.81 (95% CI 1.28–6.17); middle and lower social classes, aOR = 3.12 (95% CI 1.42–6.85); younger age, aOR = 0.97 (95% CI 0.94–0.99); and a shorter duration of illness, aOR = 0.98 (95% CI 0.97–0.99). To improve the surveillance of future epidemics, new approaches are recommended.
- 9 August 2024
- Published by MDPI AG in Epidemiologia
- Vol. 5 (3) , 499-510
Open AccessUnderreporting of Cases in the COVID-19 Outbreak of Borriana (Spain) during Mass Gathering Events in March 2020: A Cross-Sectional Study
Determining the number of cases of an epidemic is the first function of epidemiological surveillance. An important underreporting of cases was observed in many locations during the first wave of the COVID-19 pandemic. To estimate this underreporting in the COVID-19 outbreak of Borriana (Valencia Community, Spain) in March 2020, a cross-sectional study was performed in June 2020 querying the public health register. Logistic regression models were used. Of a total of 468 symptomatic COVID-19 cases diagnosed in the outbreak through anti-SARS-CoV-2 serology, 36 cases were reported (7.7%), resulting in an underreporting proportion of 92.3% (95% confidence interval [CI], 89.5–94.6%), with 13 unreported cases for every reported case. Only positive SARS-CoV-2 polymerase chain reaction cases were predominantly reported due to a limited testing capacity and following a national protocol. Significant factors associated with underreporting included no medical assistance for COVID-19 disease, with an adjusted odds ratio [aOR] of 10.83 (95% CI 2.49–47.11); no chronic illness, aOR = 2.81 (95% CI 1.28–6.17); middle and lower social classes, aOR = 3.12 (95% CI 1.42–6.85); younger age, aOR = 0.97 (95% CI 0.94–0.99); and a shorter duration of illness, aOR = 0.98 (95% CI 0.97–0.99). To improve the surveillance of future epidemics, new approaches are recommended.
- Open Access
- 27 June 2024
- Published by MDPI AG in Preprints.org
Underreporting of Cases in the COVID-19 Outbreak of Borriana (Spain) During Mass Gathering Events in March 2020: A Cross-Sectional Study.
Knowing the number of cases of an epidemic is the first function of epidemiological surveillance. An important underreporting of cases was observed in many places during the first wave of COVID-19 pandemic. To estimate this underreporting in the COVID-19 outbreak of Borriana (Valencia Community, Spain), during “Falles” mass gathering events in March 2020, a cross-sectional study was performed in June 2020 querying public health register. Logistic regression models were used. From a total of 468 symptomatic COVID-19 cases diagnosed in the outbreak by anti-SARS-CoV-2 serology, 36 cases were reported (7.7%), thus an underreporting of 92.3% (95% Confidence Interval [CI] 89.5%-94.6%), 13 unreported cases for every reported case. Only positive SARS-CoV-2 polymerase chain reaction cases were predominantly reported due to a limited testing capacity and following a national protocol. Significant factors associated with underreporting were no medical assistance for COVID-19 disease, adjusted odds ratio [aOR] 10.83 (95% CI 2.49-47.11), no chronic illness, aOR=2.81 (95% CI 1.28-6.17), middle and lower social classes, aOR=3.12 (95% CI 1.42-6.85), younger age, aOR=0.97 (95% CI 0.94-0.99), shorter duration of illness, aOR=0.98 (95% CI 0.97-0.99). To improve surveillance, studies of representative population samples are necessary to estimate the magnitude of future epidemics, and novel approaches are recommended.
- 27 June 2024
- Published by MDPI AG in Preprints.org
Open AccessUnderreporting of Cases in the COVID-19 Outbreak of Borriana (Spain) During Mass Gathering Events in March 2020: A Cross-Sectional Study.
Knowing the number of cases of an epidemic is the first function of epidemiological surveillance. An important underreporting of cases was observed in many places during the first wave of COVID-19 pandemic. To estimate this underreporting in the COVID-19 outbreak of Borriana (Valencia Community, Spain), during “Falles” mass gathering events in March 2020, a cross-sectional study was performed in June 2020 querying public health register. Logistic regression models were used. From a total of 468 symptomatic COVID-19 cases diagnosed in the outbreak by anti-SARS-CoV-2 serology, 36 cases were reported (7.7%), thus an underreporting of 92.3% (95% Confidence Interval [CI] 89.5%-94.6%), 13 unreported cases for every reported case. Only positive SARS-CoV-2 polymerase chain reaction cases were predominantly reported due to a limited testing capacity and following a national protocol. Significant factors associated with underreporting were no medical assistance for COVID-19 disease, adjusted odds ratio [aOR] 10.83 (95% CI 2.49-47.11), no chronic illness, aOR=2.81 (95% CI 1.28-6.17), middle and lower social classes, aOR=3.12 (95% CI 1.42-6.85), younger age, aOR=0.97 (95% CI 0.94-0.99), shorter duration of illness, aOR=0.98 (95% CI 0.97-0.99). To improve surveillance, studies of representative population samples are necessary to estimate the magnitude of future epidemics, and novel approaches are recommended.
- Open Access
- 10 April 2024
- Published by MDPI AG in Epidemiologia
- Vol. 5 (2) , 167-186
Cellular Immunity of SARS-CoV-2 in the Borriana COVID-19 Cohort: A Nested Case–Control Study
Our goal was to determine the cellular immune response (CIR) in a sample of the Borriana COVID-19 cohort (Spain) to identify associated factors and their relationship with infection, reinfection and sequelae. We conducted a nested case–control study using a randomly selected sample of 225 individuals aged 18 and older, including 36 individuals naïve to the SARS-CoV-2 infection and 189 infected patients. We employed flow-cytometry–based immunoassays for intracellular cytokine staining, using Wuhan and BA.2 antigens, and chemiluminescence microparticle immunoassay to detect SARS-CoV-2 antibodies. Logistic regression models were applied. A total of 215 (95.6%) participants exhibited T-cell response (TCR) to at least one antigen. Positive responses of CD4+ and CD8+ T cells were 89.8% and 85.3%, respectively. No difference in CIR was found between naïve and infected patients. Patients who experienced sequelae exhibited a higher CIR than those without. A positive correlation was observed between TCR and anti-spike IgG levels. Factors positively associated with the TCR included blood group A, number of SARS-CoV-2 vaccine doses received, and anti-N IgM; factors inversely related were the time elapsed since the last vaccine dose or infection, and blood group B. These findings contribute valuable insights into the nuanced immune landscape shaped by SARS-CoV-2 infection and vaccination.
- 10 April 2024
- Published by MDPI AG in Epidemiologia
- Vol. 5 (2) , 167-186
Open AccessCellular Immunity of SARS-CoV-2 in the Borriana COVID-19 Cohort: A Nested Case–Control Study
Our goal was to determine the cellular immune response (CIR) in a sample of the Borriana COVID-19 cohort (Spain) to identify associated factors and their relationship with infection, reinfection and sequelae. We conducted a nested case–control study using a randomly selected sample of 225 individuals aged 18 and older, including 36 individuals naïve to the SARS-CoV-2 infection and 189 infected patients. We employed flow-cytometry–based immunoassays for intracellular cytokine staining, using Wuhan and BA.2 antigens, and chemiluminescence microparticle immunoassay to detect SARS-CoV-2 antibodies. Logistic regression models were applied. A total of 215 (95.6%) participants exhibited T-cell response (TCR) to at least one antigen. Positive responses of CD4+ and CD8+ T cells were 89.8% and 85.3%, respectively. No difference in CIR was found between naïve and infected patients. Patients who experienced sequelae exhibited a higher CIR than those without. A positive correlation was observed between TCR and anti-spike IgG levels. Factors positively associated with the TCR included blood group A, number of SARS-CoV-2 vaccine doses received, and anti-N IgM; factors inversely related were the time elapsed since the last vaccine dose or infection, and blood group B. These findings contribute valuable insights into the nuanced immune landscape shaped by SARS-CoV-2 infection and vaccination.